Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for subependymal giant cell astrocytoma associated with tuberous sclerosis. 4 active patents protecting 1 drugs from 1+ originators. First major cliff: 2028. Daily refresh.

1
Approved drugs
4
Active US patents
70/100
Avg vulnerability
$600M
Annual revenue covered

Originators in Subependymal Giant Cell Astrocytoma Associated With Tuberous Sclerosis

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Novartis 4 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating subependymal giant cell astrocytoma associated with tuberous sclerosis. Each bar = one year. Y-axis scaled to peak year (4 patents).

4
28

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Afinitor
everolimus
 Novartis 4 70 $600M 2028-07-01

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01
9006224 Afinitor method of use 75 2028-07-01

Related